Neural Stem Cell Transplantation as a Therapeutic Approach for Treating Lysosomal Storage Diseases

Neurotherapeutics

Volumn 8, Issue 4, 2011, Pages 659-667

  Shihabuddin, Lamya S ^a   Cheng, Seng H ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

Cell transplantation; Lysosomal storage diseases; Neural progenitor cells; Neural stem cells; Niemann Pick A disease

Indexed keywords

LYSOSOME ENZYME; SPHINGOMYELIN PHOSPHODIESTERASE;

BLASTOCYST; CELL DIFFERENTIATION; CELL DIVISION; GENE THERAPY; IN VIVO STUDY; INNER CELL MASS; LYSOSOME; NEURAL STEM CELL TRANSPLANTATION; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH;

ANIMALS; HUMANS; LYSOSOMAL STORAGE DISEASES; NEURAL STEM CELLS; STEM CELL TRANSPLANTATION;

EID: 80955157861     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-011-0067-8     Document Type: Review

References (77)

1. Platt F, Lachmann, RH. Treating lysosomal storage disorders: current practice and future prospects. Biochim Biophys Acta 2009; 1793: 737-345.
2. Desnick RJ, Schuchman EH. Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Nat Rev Genet 2002; 3: 954-966.
3. Temple S. The development of neural stem cells. Nature 2001; 414: 112-117.
4. Gage FH. Mammalian neural stem cells. Science 2000; 287: 1433-1438.
5. Gage FH, Ray J, Fisher LJ. Isolation, characterization, and use of stem cells from the CNS. Annu Rev Neurosci 1995; 18: 159-192.
6. McKay R. Stem cells in the central nervous system. Science 1997; 276: 66-71.
7. Weiss S, Reynolds BA, Vescovi AL, Morshead C, Craig CG, van der Kooy D. Is there a neural stem cell in the mammalian forebrain? Trends Neurosci 1996; 19: 387-393.
8. Pluchino S, Zanotti L, Deleidi M, Martino G. Neural stem cells and their use as therapeutic tool in neurological disorders. Brain Res Brain Res Rev 2005; 48: 211-219.
9. Goldman S, Windrem M. Cell replacement therapy in neurological disease. Philos Trans R Soc Lond B Biol Sci 2001; 361: 1463-1475.
10. Vescovi A, Snyder EY. Establishment and properties of neural stem cell clones: plasticity in vitro and in vivo. Brain Pathol 1999; 9: 569-598.
11. Svendsen C, Caldwell MA, Ostenfeld T. Human neural stem cells: isolation, expansion and transplantation. Brain Pathol 1999; 9: 499-513.
12. Uchida N, Buck DW, He D, et al. Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci U S A 2000; 97: 14720-14725.
13. Palmer T, Schwartz PH, Taupin P, Kaspar B, Stein SA, Gage FH. Cell culture. Progenitor cells from human brain after death. Nature 2001; 411: 42-43.
14. Schwartz P, Bryant PJ, Fuja TJ, Su H, O'Dowd DK, Klassen H. Isolation and characterization of neural progenitor cells from post-mortem human cortex. J Neurosci Res 2003; 74: 838-851.
15. Weiss S, Dunne C, Hewson J, et al. Multipotent CNS stem cells are present in the adult mammalian spinal cord and ventricular neuroaxis. J Neurosci 1996; 16: 7599-7609.
16. Gage FH, Coates PW, Palmer TD, et al. Survival and differentiation of adult neuronal progenitor cells transplanted to the adult brain. Proc Natl Acad Sci U S A 1995; 92: 11879-11883.
17. Kilpatrick T, Bartlett PF. Cloned multipotential precursors from the mouse cerebrum require FGF-2, whereas glial restricted precursors are stimulated with either FGF-2 or EGF. J Neurosci 1995; 15: 3653-3661.
18. Gritti A, Parati EA, Cova L, et al. Multipotential stem cells from the adult mouse brain proliferate and self-renew in response to basic fibroblast growth factor. J Neurosci 1996; 16: 1091-1100.
19. Flax JD, Aurora S, Yang C, et al. Engraftable human neural stem cells respond to developmental cues, replace neurons, and express foreign genes. Nature Biotech 1998; 16: 1033-1039.
20. Whittemore S, Snyder EY. Physiological relevance and functional potential of central nervous system-derived cell lines. Mol Neurobiol 1996; 12: 13-38.
21. Ostenfeld T, Caldwell MA, Prowse KR, Linskens MH, Jauniaux E, Svendsen CN. Human neural precursor cells express low levels of telomerase in vitro and show diminishing cell proliferation with extensive axonal outgrowth following transplantation. Exp Neurol 2000; 164: 215-226.
22. Ray J, Gage FH. Differential properties of adult rat and mouse brain-derived neural stem/progenitor cells. Mol Cell Neurosci 2006; 31: 560-573.
23. Martinez-Serrano A, Rubio FJ, Navarro B, Bueno C, Villa A. Human neural stem and progenitor cells: in vitro and in vivo properties, and potential for gene therapy and cell replacement in the CNS. Curr Gene Ther 2001; 1: 279-299.
24. Tamaki S, Eckert K, He D, et al. Engraftment of sorted/expanded human central nervous system stem cells from fetal brain. J Neurosci Res 2002; 69: 976-986.
25. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282: 1145-1147.
26. Ludwig TE, Bergendahl V, Levenstein ME, Yu J, Probasco MD, Thomson JA. Feeder-independent culture of human embryonic stem cells. Nat Methods 2006; 3: 637-646.
27. Ludwig TE, Levenstein ME, Jones JM, et al. Derivation of human embryonic stem cells in defined conditions. Nat Biotechnol 2006; 24: 185-187.
28. Conti L, Pollard SM, Gorba T, et al. Niche-independent symmetrical self-renewal of a mammalian tissue stem cell. PLoS Biol 2005; 3: 1594-1606.
29. McDonald JW, Howard MJ. Repairing the damaged spinal cord: a summary of our early success with embryonic stem cell transplantation and remyelination. Prog Brain Res 2002; 137: 299-309.
30. Nistor GI, Totoiu MO, Haque N, Carpenter MK, Keirstead HS. Human embryonic stem cells differentiate into oligodendrocytes in high purity and myelinate after spinal cord transplantation. Glia 2005; 49: 385-396.
31. Vogel G. Cell biology. Ready or not? Human ES cells head toward the clinic. Science 2005; 308: 1534-1538.
32. Alper J. Geron gets green light for human trial of ES cell-derived product. Nat Biotechnol 2009; 27: 213-214.
33. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872.
34. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917-1920.
35. Park IH, Zhao R, West JA, et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008; 451: 141-146.
36. West MD, Vaziri H. Back to immortality: the restoration of embryonic telomere length during induced pluripotency. Regen Med 2010; 5: 485-488.
37. Kim J, Efe JA, Zhu S, et al. Direct reprogramming of mouse fibroblasts to neural progenitors. Proc Natl Acad Sci U S A 2011; 108: 7838-7843.
38. Manohar R, Lagasse E. Transdetermination: a new trend in cellular reprogramming. Mol Ther 2009; 17: 936-938.
39. Jiang Y, Henderson D, Blackstad M, Chen A, Miller RF, Verfaillie CM. Neuroectodermal differentiation from mouse multipotent adult progenitor cells. Proc Natl Acad Sci U S A 2003; 100: 11854-11860.
40. Suzuki H, Taguchi T, Tanaka H, et al. Neurospheres induced from bone marrow stromal cells are multipotent for differentiation into neuron, astrocyte, and oligodendrocyte phenotypes. Biochem Biophys Res Commun 2004; 322: 918-1022.
41. Krabbe C, Zimmer J, Meyer M. Neural transdifferentiation of mesenchymal stem cells - a critical review. APMIS 2005; 113: 831-844.
42. Kögler G, Sensken S, Airey JA, et al. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med 2004; 200: 123-135.
43. Weiss ML, Troyer DL. Stem cells in the umbilical cord. Stem Cell Rev 2006; 2: 155-162.
44. Tsai MS, Hwang SM, Tsai YL, Cheng FC, Lee, JL, Chang YJ. Clonal amniotic fluid-derived stem cells express characteristics of both mesenchymal and neural stem cells. Biol Reprod 2006; 74: 545-551.
45. Joannides A, Gaughwin P, Schwiening C, et al. Efficient generation of neural precursors from adult human skin: astrocytes promote neurogenesis from skin-derived stem cells. Lancet 2004; 364: 172-178.
46. Safford KM, Safford SD, Gimble JM, Shetty, AK, Rice HE. Characterization of neuronal/glial differentiation of murine adipose-derived adult stromal cells. Exp Neurol 2004; 187: 319-328.
47. Brustle O, Spiro AC, Karram K, Choudhary K, Okabe S, McKay RD. In vitro-generated neural precursors participate in mammalian brain development. Proc Natl Acad Sci U S A 1997; 94: 14809-14814.
48. Fricker RA, Carpenter MK, Winkler C, Greco C, Gates MA, Bjorklund A. Site-specific migration and neuronal differentiation of human neural progenitor cells after transplantation in the adult rat brain. J Neurosci 1999; 19: 5990-6005.
49. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999; 281: 249-254.
50. Sly WS, Vogler C. Brain-directed gene therapy for lysosomal storage disease: going well beyond the blood- brain barrier. Proc Natl Acad Sci U S A 2002; 99: 5760-5762.
51. Porter MT, Fluharty AL, Kihara H. Correction of abnormal cerebroside sulfate metabolism in cultured metachromatic leukodystrophy fibroblasts. Science 1971; 172: 1263-1265.
52. O'Brien JS, Miller AL, Loverde AW, Veath ML. Sanfilippo disease type B: enzyme replacement and metabolic correction in cultured fibroblasts. Science 1973; 181: 753-755.
53. Neufeld EF. Enzyme replacement therapy. In: Platt FM, Walkely SU, ed. Lysosomal disorders of the brain. Oxford: Oxford University Press, 2004: 327-338.
54. Taylor RM, Wolfe JH. Decreased lysosomal storage in the adult MPS VII mouse brain in the vicinity of grafts of retroviral vector-corrected fibroblasts secreting high levels of beta-glucuronidase. Nat Med 1997; 3: 771-774.
55. Jin HK, Carter JE, Huntley GW, Schuchman EH. Intracerebral transplantation of mesenchymal stem cells into acid sphingomyelinase-deficient mice delays the onset of neurological abnormalities and extends their life span. J Clin Invest 2002; 109: 1183-1191.
56. Buchet D, Serguera C, Zennou V, Charneau P, Mallet J. Long-term expression of beta-glucuronidase by genetically modified human neural progenitor cells grafted into the mouse central nervous system. Mol Cell Neurosci 2002; 19: 389-401.
57. Meng XL, Shen JS, Ohashi T, Maeda H, Kim SU, Eto Y. Brain transplantation of genetically engineered human neural stem cells globally corrects brain lesions in the mucopolysaccharidosis type VII mouse. J Neurosci Res 2003; 74: 266-277.
58. Shihabuddin LS, Numan S, Huff MR, et al. Intracerebral transplantation of adult mouse neural progenitor cells into the Niemann-Pick-A mouse leads to a marked decrease in lysosomal storage pathology. J Neurosci 2004; 24: 10642-10651.
59. Biffi A, De Palma M, Quattrini A, et al. Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. J Clin Invest 2004; 113: 1118-1129.
60. Snyder EY, Taylor RM, Wolfe JH. Neural progenitor cell engraftment corrects lysosomal storage throughout the MPS VII mouse brain. Nature 1995; 374: 367-370.
61. Lacorazza HD, Flax JD, Snyder EY, Jendoubi M. Expression of human beta-hexosaminidase alpha-subunit gene (the gene defect of Tay-Sachs disease) in mouse brains upon engraftment of transduced progenitor cells. Nat Med 1996; 2: 424-429.
62. Lee JP, Jeyakumar M, Gonzalez R, et al. Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease. Nat Med 2007; 13: 439-447.
63. Jeyakumar M, Lee JP, Sibson NR, et al. Neural stem cell transplantation benefits a monogenic neurometabolic disorder during the symptomatic phase of disease. Stem Cells 2009; 27: 2362-2370.
64. Tamaki SJ, Jacobs Y, Dohse M, et al. Neuroprotection of host cells by human central nervous system stem cells in a mouse model of infantile neuronal ceroid lipofuscinosis. Cell Stem Cell 2009; 5: 310-319.
65. Leventhal A, Chen W, Tall AR, Tabas I. Acid sphingomyelinase-deficient macrophages have defective cholesterol trafficking and efflux. J Biol Chem 2001; 276: 44976-44983.
66. Slotte J. Sphingomyelin-cholesterol interactions in biological and model membranes. Chem Phys Lipids 1999; 102: 13-27.
67. Viana M, Giugliani R, Leite VH, et al. Very low levels of high density lipoprotein cholesterol in four sibs of a family with non-neuropathic Niemann-Pick disease and sea-blue histiocytosis. J Med Genet 1990; 27: 499-504.
68. Sarna J, Miranda SR, Schuchman EH, Hawkes R. Patterned cerebellar Purkinje cell death in a transgenic mouse model of Niemann Pick type A/B disease. Eur J Neurosci 2001; 13: 1873-1880.
69. Yamaji A, Sekizawa Y, Emoto K, et al. Lysenin, a novel sphingomyelin-specific binding protein. J Biol Chem 1998; 273: 5300-5306.
70. Leinekugel P, Michel S, Conzelmann E, Sandhoff K. Quantitative correlation between the residual activity of beta-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease. Hum Genet 1992; 88: 513-523.
71. Sidman R, Li J, Stewart GR, et al. Injection of mouse and human neural stem cells into neonatal Niemann-Pick A model mice. Brain Res 2006; 1140: 195-204.
72. Hobert J, Dawson G. Neuronal ceroid lipofuscinoses therapeutic strategies: past, present and future. Biochim Biophys Acta 2006; 1762: 945-953.
73. Taupin P. HuCNS-SC (StemCells). Curr Opin Mol Ther 2006; 8: 156-163.
74. Worgall S, Sondhi D, Hackett NR, et al. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther 2008; 19: 463-374.
75. Kim SU, de Vellis, J. Stem cell-based cell therapy in neurological diseases: a review. J Neurosci Res 2009; 87: 2183-2200.
76. Schwartz PH, Brick DJ. Stem cell therapies for the lysosomal storage diseases - the quintessential neurodegenerative diseases. Curr Stem Cell Res Ther 2008; 3: 88-98.
77. Enns GM, Huhn, SL. Central nervous system therapy for lysosomal storage disorders. Neurosurg Focus 2008; 24: 1-12.